Capitalization 29.64B P/E ratio 2024 *
-66.4x
P/E ratio 2025 * -154x
Enterprise value 23.98B EV / Sales 2024 *
15.2x
EV / Sales 2025 * 12.5x
Free-Float
99.58%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Alnylam Pharmaceuticals, Inc.

1 day+0.93%
1 week-1.47%
Current month-2.68%
1 month+6.09%
3 months+64.45%
6 months+27.69%
Current year+23.55%
More quotes
1 week
231.01
Extreme 231.01
240.91
1 month
231.01
Extreme 231.01
263.73
Current year
141.98
Extreme 141.975
263.73
1 year
141.98
Extreme 141.975
263.73
3 years
117.58
Extreme 117.58
263.73
5 years
69.11
Extreme 69.11
263.73
10 years
31.38
Extreme 31.38
263.73
More quotes
Insider TitleAgeSince
Chief Executive Officer 61 16-09-18
Chief Tech/Sci/R&D Officer 56 14-10-28
Chief Tech/Sci/R&D Officer - 15-09-30
Insider TitleAgeSince
Founder 79 02-06-13
Director/Board Member 78 12-04-22
Chairman 63 14-06-30
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+0.93%-1.47%+22.96%+29.64% 29.64B
-2.52%-4.73%-3.92%-66.12% 46.47B
-0.02%+2.48%+4.60%-4.15% 43.53B
+0.23%+1.63%+6.46%-25.94% 42.23B
+2.22%+2.49%+28.08%-23.59% 28.11B
-0.14%-0.64%+36.74%+52.19% 27.47B
-1.53%+0.05%+34.94%+79.66% 14.94B
+1.44%-0.87%-11.72%-34.56% 12.06B
+0.97%-2.16%+7.77%-43.88% 11.35B
+6.88%-12.61%+54.64%+109.69% 11.05B
Average +0.85%-0.45%+18.06%+7.29% 26.68B
Weighted average by Cap. +0.22%+0.21%+14.40%-4.54%
See all sector performances
Ratios2024 *2025 *
Net sales 1.88B 2.32B
Net income -451M -238M
Net Debt -1.12B -593M
More financial data * Estimated data
Logo Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Employees
2,100
Calendar
More about the company
Date Price Change Volume
24-07-24 236.48 $ +0.93% 622,802
24-07-23 234.29 $ -0.55% 745,979
24-07-22 235.59 $ -0.94% 537,400
24-07-19 237.83 $ +0.48% 878,604
24-07-18 236.70 $ -1.38% 892,886

Delayed Quote Nasdaq, July 24, 2024 at 04:00 pm EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
236.48USD
Average target price
259.31USD
Spread / Average Target
+9.66%
Consensus